Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1840 1
1875 1
1878 2
1888 1
1889 2
1891 1
1896 1
1898 1
1906 1
1913 1
1915 1
1916 1
1917 1
1920 2
1922 1
1930 1
1931 1
1932 1
1935 1
1938 3
1939 1
1940 2
1941 5
1943 7
1944 2
1945 7
1946 10
1947 16
1948 16
1949 5
1950 10
1951 13
1952 10
1953 10
1954 17
1955 11
1956 8
1957 8
1958 11
1959 11
1960 11
1961 10
1962 8
1963 12
1964 14
1965 20
1966 21
1967 34
1968 31
1969 48
1970 38
1971 35
1972 33
1973 35
1974 26
1975 32
1976 42
1977 44
1978 33
1979 38
1980 43
1981 63
1982 60
1983 48
1984 47
1985 49
1986 52
1987 61
1988 69
1989 68
1990 55
1991 80
1992 75
1993 80
1994 102
1995 102
1996 83
1997 90
1998 91
1999 103
2000 132
2001 152
2002 164
2003 191
2004 173
2005 227
2006 279
2007 282
2008 297
2009 339
2010 338
2011 379
2012 441
2013 429
2014 429
2015 448
2016 493
2017 531
2018 516
2019 559
2020 626
2021 709
2022 692
2023 654
2024 645
2025 616

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,584 results

Results by year

Filters applied: . Clear all
Page 1
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Among authors: martin aj. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. Lancet. 2021. PMID: 33581798 Clinical Trial.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Buteau JP, et al. Among authors: martin aj. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16. Lancet Oncol. 2022. PMID: 36261050 Clinical Trial.
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.
Emmett L, Subramaniam S, Crumbaker M, Joshua AM, Sandhu S, Nguyen A, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Kumar ASR, Pook D, Ramdave S, Nadebaum DP, Voskoboynik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, McJannett M, Thomas H, Langford A, Hofman MS, Martin AJ, Davis ID, Stockler MR; ENZA-p Trial Investigators; Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Emmett L, et al. Among authors: martin aj. Lancet Oncol. 2025 Mar;26(3):291-299. doi: 10.1016/S1470-2045(25)00009-9. Epub 2025 Feb 13. Lancet Oncol. 2025. PMID: 39956124 Clinical Trial.
Targeted Long-Read Sequencing as a Single Assay Improves the Diagnosis of Spastic-Ataxia Disorders.
Rudaks LI, Stevanovski I, Yeow D, Reis ALM, Chintalaphani SR, Cheong PL, Gamaarachchi H, Worgan L, Ahmad K, Hayes M, Hannaford A, Kim S, Fung VSC, Halmagyi GM, Martin A, Manser D, Tchan M, Ng K, Kennerson ML, Deveson IW, Kumar KR. Rudaks LI, et al. Among authors: martin a. Ann Clin Transl Neurol. 2025 Apr;12(4):832-841. doi: 10.1002/acn3.70008. Epub 2025 Feb 25. Ann Clin Transl Neurol. 2025. PMID: 40007153 Free PMC article.
Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
De Corso E, Canonica GW, Heffler E, Springer M, Grzegorzek T, Viana M, Horváth Z, Mullol J, Gevaert P, Michel J, Peters AT, Wagenmann M, Zaghloul S, Zhang M, Corbett M, Nash S, Angello JT, Radwan A, Deniz Y, Martin A, Hellings PW. De Corso E, et al. Among authors: martin a. Lancet Respir Med. 2025 Sep 28:S2213-2600(25)00287-5. doi: 10.1016/S2213-2600(25)00287-5. Online ahead of print. Lancet Respir Med. 2025. PMID: 41033334
TP53 Mutations Detected by NGS Are a Major Clinical Risk Factor for Stratifying Mantle Cell Lymphoma.
Lazarian G, Chemali L, Bensalah M, Zindel C, Lefebvre V, Thieblemont C, Martin A, Tueur G, Letestu R, Fleury C, Leymarie V, Vidal V, Bidet A, Maitre E, Cymbalista F, Levy V, Soussi T, Baran-Marszak F. Lazarian G, et al. Among authors: martin a. Am J Hematol. 2025 May;100(5):933-936. doi: 10.1002/ajh.27650. Epub 2025 Mar 6. Am J Hematol. 2025. PMID: 40047370 No abstract available.
Connexin46 in the nucleus of cancer cells: a possible role as transcription modulator.
Fernández-Olivares A, Orellana VP, Llanquinao J, Nuñez G, Pérez-Moreno P, Contreras-Riquelme S, Martin AJ, Mammano F, Alfaro IE, Calderón JF, Stehberg J, Sáez MA, Retamal MA. Fernández-Olivares A, et al. Among authors: martin aj. Cell Commun Signal. 2025 Mar 27;23(1):153. doi: 10.1186/s12964-025-02151-w. Cell Commun Signal. 2025. PMID: 40148950 Free PMC article.
11,584 results
You have reached the last available page of results. Please see the User Guide for more information.